Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition with synergistic effect and myofibroblast capable of resisting organ fibrosis and tumor stroma and application

A myofibroblast, synergistic technology, applied in the field of biomedicine to achieve the effect of safe clinical use

Inactive Publication Date: 2015-09-02
魏华
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] So far, we have not seen the combination of tetrandrine and tetrandrine derivatives and baicalein and baicalein derivatives at home and abroad for anti-myofibroblasts, treatment of organ fibrosis, interference and influence on tumor stroma, for Inhibition of tumor cell growth, metastasis and invasion derivatives reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition with synergistic effect and myofibroblast capable of resisting organ fibrosis and tumor stroma and application
  • Pharmaceutical composition with synergistic effect and myofibroblast capable of resisting organ fibrosis and tumor stroma and application
  • Pharmaceutical composition with synergistic effect and myofibroblast capable of resisting organ fibrosis and tumor stroma and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0052] The invention provides a drug combination method of tetrandrine and baicalein. The drug combination has a synergistic effect against myofibroblasts and has no cytotoxic effect, and is used for treating organ fibrosis and inhibiting tumor cell proliferation, migration and invasion.

[0053] The present invention is further described in conjunction with the following examples, but the present invention is not limited in any form.

[0054] Experimental Methods and Detection

[0055] Materials and methods

[0056] Tetrandrine and baicalein were purchased from Sigma (St Louis, Mo.). The solvent dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Itasca, 111). We used human cardiac fibroblasts (herein referred to as fibroblasts) as a representative of organ fibroblasts response to drug combinations; human colorectal tumor-associated fibroblasts (herein referred to as tumor-associated fibroblasts) Representative of responses to drug combinations. Colorectal tu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition with a synergistic effect and myofibroblast capable of resisting organ fibrosis and tumor stroma. The pharmaceutical composition is composed of tetrandrine, a tetrandrine derivative, baicalein and a baicalein derivative, has the synergistic effect and the myofibroblast capable of resisting organ fibrosis and tumor stroma, is capable of reducing expression of myofibroblast alpha-smooth muscle actin (alpha-SMA), enables the myofibroblast alpha-smooth muscle actin (alpha-SMA) to be restored to fibroblast in resting time, and is used for treating organ fibrosis and suppressing tumor growth, metastasis and infiltration. The pharmaceutical composition has no obvious toxic or side effects on fibroblast while obviously reducing expression of alpha-SMA.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and more specifically relates to a synergistic anti-myofibroblast drug combination and its application. The drug combination has a synergistic effect against myofibroblasts of fibrotic organs and tumor stroma. The drug combination reduces the dosage of a single drug and overcomes the toxic effect of the drug on cells. It is used to reduce scarring, treat organ fibrosis and inhibit tumor growth, metastasis and invasion. Background technique [0002] 1. Myofibroblasts [0003] Myofibroblasts are defined as fibroblasts activated in vivo or in vitro to transform into another cell form that has the characteristics of fibroblasts and smooth muscle contractile fibers (expressing α-SMA), called myofibroblasts 1 .Myofibroblasts are found in many organs and play a major role in normal and pathological tissue repair 2 . Consistent with fibroblasts, myofibroblasts are polygenic (originating from dif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4748A61P35/00A61P35/04A61P11/00A61P1/16A61P9/00A61P25/28A61P17/00A61K31/352
Inventor 魏华张湘云
Owner 魏华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com